oncolex logo
Utskriftsdato 6.6.2020

Referanser til kreft i svelg

  1. Cancer in Norway 2018, Cancer Registry of Norway, Institute of Population-based Research. Oslo, Norway
  2. Thawley SE, Panje WR, Batsakis JG, Lindberg WB. Comprehensive Management of Head and Neck Tumors. 2. opplag. W.B. Philadelphia: Saunders Company, 1999 
  3. Sobin LH, Wittekind C, eds. TNM Classification of Malignant Tumours. 6th ed. New York: Wiley-Liss, 2002
  4. Wittekind C, Greene FL, Hutter RVP, Klimpfinger M, Sobin LH. TNM Atlas. 5. ed. Heidelberg: Springer, 2005
  5. Janfaza P, Nadol JB, Galla R, Fabien RL. Surgical anatomy of the head and neck. Lipincott, Williams & Wilkins, 2001
  6. Boysen M, Lövdal O, Tausjö J, Winther F. The value of follow-up in patients treated for squamous cell carcinoma of the head and neck. Eur J Cancer 1992; 28: 455-60 
  7. Boysen M, Loven JØ. Second malignant neoplasms in patients with head and neck squamous cell carcinomas. Acta Oncol. 1993; 32: 283-288 
  8. Rosenquist K. Risk factors in oral and oropharyngeal squamous cell carcinoma. Doctoral Thesis. Centre for Oral Health Sciences, Malmö University, 2005
  9. Mork J, Møller B, Glattre E. Familial risk in head and neck squamous cell carcinoma diagnosed before the age of 45: a population based study. Oral Oncol 1999; 35 (4): 360-7
  10. Abenstein H, Nordgren M, Boysen M, Jannert M, SIlander E et al. Quality of life and head and neck cancer: a 5 year prospective study. Laryngoscope 2005; 115 (12):2183–2192.
  11. Hannisdal K, Schjølberg A, De Angelis PM, Boysen M, Clausen OPF. Human papillomavirus (HPV)-positive tonsillar carcinomas are frequent and have a favourable prognosis in males in Norway. Acta Oto-Laryng. In press may 2009
  12. Boysen M. Squamous cell carcinoma of the head and neck in the elderly. The open Otolaryngology Journal. In press. 2010.
  13. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New Engl J Med 2006;354:567-78

  14. Vermorken JB, Trigo J, Hitt R et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum- based therapy. J Clin Oncol 2007;25:2171-7.